This report was recently updated on April 18 2024 with the latest and most recent
market numbers
Global Tuberculosis Therapeutics Market Size, Trends & Analysis - Forecasts to 2026 By Disease Type (Active TB and Latent TB), By Therapy (First-Line and Second-Line), By Region (North America, Asia Pacific, CSA, Europe, and The Middle East and Africa); Competitive Landscape, Company Market Share Analysis, and Competitor Analysis
Tuberculosis is triggered by a bacterium named Mycobacterium tuberculosis whose primary area of infection is the lungs but may often damage other organs of the body. The basic way of transmission of Tuberculosis is via the air; when a person infected with Tuberculosis comes into contact with another person, this leads to the transmission of the infection by talking, coughing, or sneezing. The disease is quite fatal and needs on-time diagnosis & proper treatment or else the person can also succumb to the disease. The symptoms of this disease are excessive cough, weight loss, fever, insomnia, and vomiting. If a patient is suffering from these symptoms, then in order to treat the patient on time, the diagnosis has to be done immediately, which can be accomplished by various tests such as, Chest X-Ray, Acid-Fast Bacillus (AFB) Tests, Testing for TB Infection, Tuberculin Skin Testing, and Tuberculosis Screening.
According to the World Health Organization's 2020 Global Tuberculosis (TB) Study, 1.5 million individuals died from tuberculosis in 2018. Tuberculosis is one of the top ten reasons for mortality globally, and the main source trigger is by a specific infectious agent. Overall, the worldwide threat of tuberculosis and multidrug-resistant tuberculosis poses a risk to prominent medical regulatory organizations. The proactive participation of both the medical community & the government in combating tuberculosis is likely to raise the volume of Tuberculosis diagnoses. This, in particular, it is propelling the global tuberculosis therapeutics market, which is being fueled by the rising national and international proliferation of TB and MDR-TB.
The rising prevalence of tuberculosis would provide attractive prospects for the global tuberculosis therapeutics industry. As per the World Health Organization, about one-third of the global population has persistent tuberculosis. Underdeveloped & emerging countries have a higher prevalence of tuberculosis reports. Patients who are HIV-positive are more susceptible to suffer from persistent tuberculosis. People with a vulnerable immune system as well as those suffering from other diseases are at a heightened likelihood of developing active tuberculosis. The WHO organization created a tuberculosis treatment program known as ‘Directly Observed Treatment, Short Course' which has seen rapid growth of the global tuberculosis therapeutics market. The scarcity of anti-tubercular medications for managing tuberculosis in kids would have a negative impact on the market. Moreover, the factors that are acting as a restraint to the market are the lack of medical resources available in all countries for timely detection and medication.
The number of hospitals and clinics dedicated to tuberculosis diagnosis and treatments has been increasing in every country. Globally, governments are showing special interest in the treatment of Tuberculosis as the disease is impossible to get detected in all the areas due to a dearth of economic resources and also lack of good medical services. TB is an infectious disease and hence, several governments have launched campaigns where free medications are being provided. These aforementioned factors are driving growth in the tuberculosis therapeutics market.
Based on disease type, tuberculosis therapeutics can be segregated into active TB and latent TB. The active tuberculosis (ATB) segment is likely to dominate the market due to an increase in the number of DS and MDR TB incidents, which can be credited to insufficient care patterns in high-risk areas. As per the Centers for Disease Control and Prevention (CDC), 9 million people worldwide develop active tuberculosis (TB) each year. Although ATB is the primary target in this market, developed economies with low TB threat but higher migrant influx and demographic mobility are focusing on care for latent tuberculosis (LTBI) cases.
Based on therapy, tuberculosis therapeutics can be segregated into first-line and second-line. Second-line therapy is presumed to be the leading segment. The rising prevalence of MDR TB, increasing national monitoring activities, and global interventions led by WHO and the Global Drug Facility (GDF) have all contributed to the development of this segment. As a result, the rise of drug-resistant disorder reports has increased the need for and use of second-line treatment. The segment's high sales share in the global market is also due to the cost-intensive layout of MDR TB products.
As per the geographical analysis, the market can be classified into North America (the United States, Canada, and Mexico), Asia Pacific (India, China, Japan, Malaysia, Singapore, and Rest of Asia Pacific), Europe (Germany, United Kingdom, Italy, France, Spain, Netherlands, and Rest of Europe), Middle East & Africa (Saudi Arabia, United Arab Emirates, and Rest of the Middle East & Africa) and Central & South America (Brazil, Argentina, and Rest of Central and South America). North America is presumed to dominate the tuberculosis therapeutics market because this region is at the forefront of medicine manufacturing and advancement in medical technologies. Medical facilities for curing the disease and capability & systems for diagnostics of TB are much more advanced in North America. Moreover, the supremacy is attributable to the fact that North America is the world leader in medical research and development programs. Moreover, a well-established drug approval process and widespread use of the BCG vaccine are leading to global supremacy. The Asia Pacific is presumed to be the fastest-growing tuberculosis therapeutics market. This can be due to the disease's elevating proliferation, growing incidence of HIV-TB co-infection, increasing demographic awareness of the dangers of drug adherence, and improved healthcare facilities. Furthermore, the majority of global pharmaceutical firms have established a presence in emerging economies such as India and China, which is likely to expand therapeutic access and fuel market growth.
Lupin, Macleods Pharmaceuticals Ltd, Otsuka Pharmaceutical Co. Ltd, Johnson & Johnson (J & J) Services, Novartis AG, Sigma Pharmaceutical Pvt. Ltd., Aventis Pharmaceuticals Ltd., Hoffmann-La Roche Ltd., VersaPharm Inc., Sanofi Aventis, and Bayer among others, are the top players in the tuberculosis therapeutics market.
Novartis International AG announced in December 2020 that it will be acquiring Cadent Therapeutics which will be done in the 1st quarter of 2021, which was to be done in 2 phases. The 1st phase was CAD-9303 – the schizophrenia program and the 2nd phase was CAD-1883 – movement disorder research.
Please note: This is not an exhaustive list of companies profiled in the report.
Chapter 1 Methodology
1.1 Market Scope & Definitions
1.2 Estimates & Forecast Calculation
1.3 Historical Data Overview And Validation
1.4 Data Sources
1.4.1 Secondary
1.4.2 Primary
Chapter 2 Report Outlook
2.1 Tuberculosis Therapeutics Market Overview, 2016-2026
2.1.1 Industry Overview
2.1.2 Disease Type Overview
2.1.3 Therapy Overview
2.1.4 Regional Overview
Chapter 3 Tuberculosis Therapeutics Market Trends
3.1 Market Segmentation
3.2 Industry Background, 2016-2026
3.3 Market Key Trends
3.3.1 Positive Trends
3.3.1.1 High prevalence of Tuberculosis cases
3.3.1.2 Increasing R&D Investments and New Drug Developments
3.3.2 Industry Challenges
3.3.2.1 The Increasing Incidence of Drug Recall
3.4 Prospective Growth Scenario
3.4.1 Disease Type Growth Scenario
3.4.2 Therapy Growth Scenario
3.5 COVID-19 Influence over Industry Growth
3.6 Porter’s Analysis
3.7 PESTEL Analysis
3.8 Value Chain & Supply Chain Analysis
3.9 Regulatory Framework
3.9.1 North America
3.9.2 Europe
3.9.3 APAC
3.9.4 LATAM
3.9.5 MEA
3.10 Technology Overview
3.11 Market Share Analysis, 2020
3.11.1 Company Positioning Overview, 2020
Chapter 4 Tuberculosis Therapeutics Market, By Disease Type
4.1 Disease Type Outlook
4.2 Active TB
4.2.1 Market Size, By Region, 2016-2026 (USD Million)
4.3 Latent TB
4.3.1 Market Size, By Region, 2016-2026 (USD Million)
Chapter 5 Tuberculosis Therapeutics Market, By Therapy
5.1 Therapy Outlook
5.2 First-Line
5.2.1 Market Size, By Region, 2016-2026 (USD Million)
5.3 Second-Line
5.3.1 Market Size, By Region, 2016-2026 (USD Million)
Chapter 6 Tuberculosis Therapeutics Market, By Region
6.1 Regional outlook
6.2 North America
6.2.1 Market Size, By Country 2016-2026 (USD Million)
6.2.2 Market Size, By Disease Type, 2016-2026 (USD Million)
6.2.3 Market Size, By Therapy, 2016-2026 (USD Million)
6.2.4 U.S.
6.2.4.1 Market Size, By Disease Type, 2016-2026 (USD Million)
6.2.4.2 Market Size, By Therapy, 2016-2026 (USD Million)
6.2.5 Canada
6.2.5.1 Market Size, By Disease Type, 2016-2026 (USD Million)
6.2.5.2 Market Size, By Therapy, 2016-2026 (USD Million)
6.3 Europe
6.3.1 Market Size, By Country 2016-2026 (USD Million)
6.3.2 Market Size, By Disease Type, 2016-2026 (USD Million)
6.3.3 Market Size, By Therapy, 2016-2026 (USD Million)
6.3.4 Germany
6.3.4.1 Market Size, By Disease Type, 2016-2026 (USD Million)
6.3.4.2 Market Size, By Therapy, 2016-2026 (USD Million)
6.3.5 UK
6.3.5.1 Market Size, By Disease Type, 2016-2026 (USD Million)
6.3.5.2 Market Size, By Therapy, 2016-2026 (USD Million)
6.3.6 France
6.3.6.1 Market Size, By Disease Type, 2016-2026 (USD Million)
6.3.6.2 Market Size, By Therapy, 2016-2026 (USD Million)
6.3.7 Italy
6.3.7.1 Market Size, By Disease Type, 2016-2026 (USD Million)
6.3.7.2 Market Size, By Therapy, 2016-2026 (USD Million)
6.3.8 Spain
6.3.8.1 Market Size, By Disease Type, 2016-2026 (USD Million)
6.3.8.2 Market Size, By Therapy, 2016-2026 (USD Million)
6.3.9 Russia
6.3.9.1 Market Size, By Disease Type, 2016-2026 (USD Million)
6.3.9.2 Market Size, By Therapy, 2016-2026 (USD Million)
6.4 Asia Pacific
6.4.1 Market Size, By Country 2016-2026 (USD Million)
6.4.2 Market Size, By Disease Type, 2016-2026 (USD Million)
6.4.3 Market Size, By Therapy, 2016-2026 (USD Million)
6.4.4 China
6.4.4.1 Market Size, By Disease Type, 2016-2026 (USD Million)
6.4.4.2 Market Size, By Therapy, 2016-2026 (USD Million)
6.4.5 India
6.4.5.1 Market Size, By Disease Type, 2016-2026 (USD Million)
6.4.5.2 Market Size, By Therapy, 2016-2026 (USD Million)
6.4.6 Japan
6.4.6.1 Market Size, By Disease Type, 2016-2026 (USD Million)
6.4.6.2 Market Size, By Therapy, 2016-2026 (USD Million)
6.4.7 Australia
6.4.7.1 Market Size, By Disease Type, 2016-2026 (USD Million)
6.4.7.2 Market size, By Therapy, 2016-2026 (USD Million)
6.4.8 South Korea
6.4.8.1 Market Size, By Disease Type, 2016-2026 (USD Million)
6.4.8.2 Market Size, By Therapy, 2016-2026 (USD Million)
6.5 Latin America
6.5.1 Market Size, By Country 2016-2026 (USD Million)
6.5.2 Market Size, By Disease Type, 2016-2026 (USD Million)
6.5.3 Market Size, By Therapy, 2016-2026 (USD Million)
6.5.4 Brazil
6.5.4.1 Market Size, By Disease Type, 2016-2026 (USD Million)
6.5.4.2 Market Size, By Therapy, 2016-2026 (USD Million)
6.5.5 Mexico
6.5.5.1 Market Size, By Disease Type, 2016-2026 (USD Million)
6.5.5.2 Market Size, By Therapy, 2016-2026 (USD Million)
6.5.6 Argentina
6.5.6.1 Market Size, By Disease Type, 2016-2026 (USD Million)
6.5.6.2 Market Size, By Therapy, 2016-2026 (USD Million)
6.6 MEA
6.6.1 Market Size, By Country 2016-2026 (USD Million)
6.6.2 Market Size, By Disease Type, 2016-2026 (USD Million)
6.6.3 Market Size, By Therapy, 2016-2026 (USD Million)
6.6.4 Saudi Arabia
6.6.4.1 Market Size, By Disease Type, 2016-2026 (USD Million)
6.6.4.2 Market Size, By Therapy, 2016-2026 (USD Million)
6.6.5 UAE
6.6.5.1 Market Size, By Disease Type, 2016-2026 (USD Million)
6.6.5.2 Market Size, By Therapy, 2016-2026 (USD Million)
6.6.6 South Africa
6.6.6.1 Market Size, By Disease Type, 2016-2026 (USD Million)
6.6.6.2 Market Size, By Therapy, 2016-2026 (USD Million)
Chapter 7 Company Landscape
7.1 Competitive Analysis, 2020
7.2 Lupin
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Strategic Positioning
7.2.4 Info Graphic Analysis
7.3 Macleods Pharmaceuticals Ltd.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Strategic Positioning
7.3.4 Info Graphic Analysis
7.4 Otsuka Pharmaceutical Co. Ltd
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Strategic Positioning
7.4.4 Info Graphic Analysis
7.5 Johnson & Johnson (J&J) Services
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Strategic Positioning
7.5.4 Info Graphic Analysis
7.6 Novartis AG
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Strategic Positioning
7.6.4 Info Graphic Analysis
7.7 Sigma Pharmaceutical Pvt. Ltd.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Strategic Positioning
7.7.4 Info Graphic Analysis
7.8 Aventis Pharmaceuticals Ltd
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Strategic Positioning
7.8.4 Info Graphic Analysis
7.9 Hoffmann-La Roche Ltd.
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Strategic Positioning
7.9.4 Info Graphic Analysis
7.10 VersaPharm Inc.
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Strategic Positioning
7.10.4 Info Graphic Analysis
7.11 Sanofi Aventis
7.11.1 Company Overview
7.11.2 Financial Analysis
7.11.3 Strategic Positioning
7.11.4 Info Graphic Analysis
7.12 Bayer
7.12.1 Company Overview
7.12.2 Financial Analysis
7.12.3 Strategic Positioning
7.12.4 Info Graphic Analysis
7.13 Other Companies
7.13.1 Company Overview
7.13.2 Financial Analysis
7.13.3 Strategic Positioning
7.13.4 Info Graphic Analysis
The Global Tuberculosis Therapeutics Market has been studied from the year 2019 till 2026. However, the CAGR provided in the report is from the year 2021 to 2026. The research methodology involved three stages: Desk research, Primary research, and Analysis & Output from the entire research process.
The desk research involved a robust background study which meant referring to paid and unpaid databases to understand the market dynamics; mapping contracts from press releases; identifying the key players in the market, studying their product portfolio, competition level, annual reports/SEC filings & investor presentations; and learning the demand and supply-side analysis for the Tuberculosis Therapeutics Market.
The primary research activity included telephonic conversations with more than 50 tier 1 industry consultants, distributors, and end-use product manufacturers.
Finally, based on the above thorough research process, an in-depth analysis was carried out considering the following aspects: market attractiveness, current & future market trends, market share analysis, SWOT analysis of the company and customer analytics.
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
Or view our licence options:
Tailor made solutions just for you
80% of our clients seek made-to-order reports. How do you want us to tailor yours?
OUR CLIENTS
